{
    "clinical_study": {
        "@rank": "48781", 
        "acronym": "HIPPO", 
        "arm_group": [
            {
                "arm_group_label": "Hippocampal sparing whole brain RT", 
                "arm_group_type": "Experimental", 
                "description": "30 Gy in 10 fractions hippocampal sparing whole brain radiotherapy will be administered by Helical Tomotherapy, IMRT, or VMAT"
            }, 
            {
                "arm_group_label": "Control: Conventional whole brain RT", 
                "arm_group_type": "Active Comparator", 
                "description": "30 Gy in 10 fractions conventional whole brain radiotherapy will be administered"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate whether sparing the hippocampi during whole brain\n      radiotherapy following neurosurgery or stereotactic radiosurgery in patients with brain\n      metastases from a systemic tumour helps preserve brain function."
        }, 
        "brief_title": "Hippocampal Sparing Whole Brain Radiotherapy vs Conventional Whole Brain Radiotherapy in Patients With Brain Metastases", 
        "completion_date": {
            "#text": "August 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Brain Metastases", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasm Metastasis", 
                "Neoplasms, Second Primary", 
                "Brain Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 16  years\n\n          -  Karnofsky Performance Status (KPS) \u2265 70\n\n          -  Brain metastases from systemic malignancy which has been histologically confirmed\n             (from the primary or any metastatic site)\n\n          -  In total, at most 4 distinct brain metastases based on MRI imaging with contrast at\n             any prior time-points\n\n          -  Each of the brain metastases must either be in complete radiological remission on\n             contrast MRI imaging, or have been treated by neurosurgery or by SRS in line with UK\n             SRS commissioning guidelines within the following timeframes:\n\n               -  If treated by neurosurgery only, the patient must be registered within 4 weeks\n                  of the date of neurosurgery (or of the first neurosurgery)\n\n               -  If treated by SRS only, the patient must be registered within 4 weeks of\n                  treatment to each individual metastasis being completed (i.e. within 4 weeks of\n                  the last SRS fraction to each metastasis)\n\n               -  If treated by both neurosurgery and SRS, then the patient must be registered\n                  within 6 weeks of the treatment to each individual metastasis being completed\n                  (i.e. within 6 weeks of the neurosurgery and within 6 weeks of the last SRS\n                  fraction to each metastasis)\n\n          -  Ability to complete NCF test battery (including ability to speak English)\n\n          -  Willing and able to give consent and to comply with treatment and follow up schedule\n\n        Exclusion Criteria:\n\n          -  Metastases from small cell carcinoma, haematological malignancy, or central nervous\n             system malignancy\n\n          -  Leptomeningeal metastases\n\n          -  Contraindication to MRI imaging with contrast\n\n          -  Prior radiotherapy to the brain, apart from SRS for brain metastases completed within\n             6 weeks of trial registration\n\n          -  Metastases currently or previously within 5 mm of either hippocampus\n\n          -  Disease specific graded prognostic assessment (DS-GPA) score \u2264 1.0 for any of the\n             histologies for which DS-GPA has been defined [Sperduto 2012]\n\n          -  Women of childbearing potential who are known to be pregnant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "84", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02147028", 
            "org_study_id": "UCL/12/0512", 
            "secondary_id": "Cancer Research UK"
        }, 
        "intervention": [
            {
                "arm_group_label": "Hippocampal sparing whole brain RT", 
                "description": "30 Gy in 10 fractions hippocampal sparing whole brain radiotherapy will be administered by Helical Tomotherapy, IMRT, or VMAT", 
                "intervention_name": "Hippocampal sparing whole brain radiotherapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Control: Conventional whole brain RT", 
                "description": "30 Gy in 10 fractions conventional whole brain radiotherapy will be administered", 
                "intervention_name": "Conventional whole brain radiotherapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "whole brain RT", 
            "hippocampal sparing", 
            "neurocognitive function"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "location": {
            "contact": {
                "email": "gillian.whitfield@christie.nhs.uk", 
                "last_name": "Gillian Whitfield"
            }, 
            "facility": {
                "address": {
                    "city": "Manchester", 
                    "country": "United Kingdom", 
                    "zip": "M20 4BX"
                }, 
                "name": "The Christie NHS Foundation Trust"
            }, 
            "investigator": {
                "last_name": "Gillian Whitfield", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Phase II Trial of Hippocampal Sparing Versus Conventional Whole Brain Radiotherapy After Surgical Resection or Radiosurgery in Favourable Prognosis Patients With 1-4 Brain Metastases", 
        "overall_contact": {
            "email": "ctc.hippo@ucl.ac.uk", 
            "last_name": "Katharina Wanek", 
            "phone": "0207 679 9116"
        }, 
        "overall_contact_backup": {
            "email": "ctc.hippo@ucl.ac.uk", 
            "last_name": "Laura Clifton-Hadley", 
            "phone": "0207 679 9138"
        }, 
        "overall_official": {
            "affiliation": "The Christie NHS Foundation Trust", 
            "last_name": "Gillian Whitfield, MA,MB BS,PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: National Institute for Health Research", 
                "United Kingdom: Research Ethics Committee", 
                "United Kingdom: National Health Service"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A decline in total recall will be assessed as being clinically significant if there is at least a 5 point decrease in total recall score at 4 months, compared to baseline [Jacobson 1991, Brandt 1998]", 
            "measure": "Total recall assessed using Hopkins Verbal Learning Test-Revised (HVTLR) at 4 months", 
            "safety_issue": "No", 
            "time_frame": "4 months after completion of WBRT or HS-WBRT"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02147028"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "NCF, using a 30-60 min test battery (Memory - HVLT-R, Wechsler Memory Scale (logical memory subtest), Rey figure test, Wechsler digit span; Attention - Test of Everyday Attention (map search subtest), Trail Making Test (Parts A and B); Language - Graded Naming Test); this may be revised in the light of forthcoming recommendations on NCF assessment in brain metastases trials by the RANO (Revised Assessment in Neuro-oncology) working party", 
                "measure": "Neurocognitive function", 
                "safety_issue": "No", 
                "time_frame": "4, 6, 12 and 24 months after completion of WBRT or HS-WBRT"
            }, 
            {
                "description": "Quality of life will be assessed using EORTC QLQ C30 and BN20", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "2, 4, 6, 9, 12, 18 and 24 months after completion of WBRT or HS-WBRT"
            }, 
            {
                "description": "The duration of functional independence will be assessed as the time for which the Karnofsky Performance Status \u2265 70", 
                "measure": "Length of time functionally independent", 
                "safety_issue": "No", 
                "time_frame": "2, 4, 6, 9, 12, 18 and 24 months after completion of WBRT or HS-WBRT"
            }, 
            {
                "description": "Incidence of metastases within the perihippocampal region, local control, and intracranial control will be assessed on the basis of MRI imaging", 
                "measure": "Local control of surgery/SRS treated metastases, local and distant intracranial control (treated and new metastases), and disease control within the hippocampal regions", 
                "safety_issue": "No", 
                "time_frame": "2, 4, 6, 9, 12, 18 and 24 months after completion of WBRT or HS-WBRT"
            }, 
            {
                "description": "Date of death will be determined from the medical records, or from the GP", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "followed up until 24 months after completion of WBRT or HS-WBRT"
            }, 
            {
                "description": "Steroid and antiepileptic medication use will be recorded in  patient diaries and assessed at clinic visits", 
                "measure": "Steroid and antiepileptic medication requirements", 
                "safety_issue": "No", 
                "time_frame": "2, 4, 6, 9, 12, 18 and 24 months after completion of WBRT or HS-WBRT"
            }, 
            {
                "description": "Acute and late side effects of radiotherapy will be assessed using NCI CTCAE scale v4.03", 
                "measure": "Acute and late side effects of radiotherapy", 
                "safety_issue": "Yes", 
                "time_frame": "2, 4, 6, 9, 12, 18 and 24 months after completion of WBRT or HS-WBRT"
            }
        ], 
        "source": "University College, London", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Cancer Research UK", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The Brain Tumour Charity", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University College, London", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}